Beginning Cash: The amount of cash reported by the company on its previous statement.
Denali Therapeutics Inc. (DNLI) had Beginning Cash of $208.43M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-128.45M |
|
-- |
|
-- |
|
$137.36M |
|
$-137.36M |
|
$8.91M |
|
$-128.45M |
|
$-128.45M |
|
$-128.45M |
|
$-128.45M |
|
$-128.45M |
|
$-128.45M |
|
$-137.36M |
|
$-135.77M |
|
186.64M |
|
186.64M |
|
$-0.69 |
|
$-0.69 |
|
| Balance Sheet Financials | |
$1.02B |
|
$51.73M |
|
$243.27M |
|
$1.27B |
|
$110.16M |
|
$5.51M |
|
$229.77M |
|
$339.93M |
|
$926.10M |
|
$890.10M |
|
$926.10M |
|
158.66M |
|
| Cash Flow Statement Financials | |
$-131.20M |
|
$94.46M |
|
$219.04M |
|
|
Beginning Cash |
$208.43M |
$390.73M |
|
$182.30M |
|
$23.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.28 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-133.67M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.87% |
|
-14.43% |
|
-10.15% |
|
-13.79% |
|
$5.84 |
|
$-0.72 |
|
$-0.70 |
|